Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BISCUIT: Phase 3 open-label remibrutinib in Japanese adults with chronic spontaneous urticaria
jRCT2061210066Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of remibrutinib in chronic idiopathic urticaria (CIU), sponsored by Novartis. Primary endpoint: Treatment-emergent adverse events. Started Jan 2022; status: completed.
02
Drugs
remibrutinib
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on jRCT2061210066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061210066.